Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vertex’s ‘Slow Train To Pain’ R&D Rolls On

VX-548 Moves To Phase II

Executive Summary

Vertex is advancing its sodium channel inhibitor VX-548 to mid-stage trials in the second half of the year as a potential treatment for pain after bunionectomy and abdominoplasty procedures.

You may also be interested in...



Bluebird’s Latest Gene Therapy Stumble Will Help Vertex Close The Gap

Once the darling of biotech investors, Bluebird Bio’s go-it-alone strategy with Zynteglo has not paid off as German launch plans stall.

Merck Makes Its Debut In Pain With Pioneering New Analgesic Class

Merck & Co is moving into analgesia with a deal signed with Kings College London for an early program that has the potential to create a novel class of pain medications with reduced side effects.

Vertex Pain Product VX-150 Comes Out Of The Shadows

Solid Phase II efficacy data for Vertex’s pain product have brought it blinking into the light. Analysts are hoping it will lead to an additional revenue stream for Vertex behind its all-conquering cystic fibrosis franchise.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144293

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel